Abstract
Of the tropical diseases, trypanosomiases and leishmaniases should most concern the pharmaceutical community because of their high prevalence in developing countries and the lack of effective drug treatments. Despite this, they have not historically received much attention in terms of investment and research effort, nor do they now. In very recent years, thanks to the involvement of several nonprofit organizations, the chemotherapeutic options have expanded with the introduction of the first combination therapy. The optimal efficacy and safety of nifurtimox – eflornithine combination against second-stage human African trypanosomiasis is an encouraging first step towards simpler and more affordable therapies. Along the same line, I propose that single chemical entities able to modulate more than one target may prove more efficacious and tolerable than the available arsenal of drugs. Herein, I discuss the pros and cons of this approach, together with examples taken from the recent literature.
Keywords: Neglected tropical diseases, combination therapy, multitarget drug discovery, hybrid compounds, leishmaniasis, trypanosomiasis, multitarget ligands, Nifurtimox benznidazole, toxic organic compound, mucocutaneous disease, chronic human trypanosomiasis, therapeutic compounds, antiretroviral treatment, visceralleishmaniases, axenic amastigote
Current Topics in Medicinal Chemistry
Title: Multi-Target-Directed Ligands as Innovative Tools to Combat Trypanosomatid Diseases
Volume: 11 Issue: 22
Author(s): Maria Laura Bolognesi
Affiliation:
Keywords: Neglected tropical diseases, combination therapy, multitarget drug discovery, hybrid compounds, leishmaniasis, trypanosomiasis, multitarget ligands, Nifurtimox benznidazole, toxic organic compound, mucocutaneous disease, chronic human trypanosomiasis, therapeutic compounds, antiretroviral treatment, visceralleishmaniases, axenic amastigote
Abstract: Of the tropical diseases, trypanosomiases and leishmaniases should most concern the pharmaceutical community because of their high prevalence in developing countries and the lack of effective drug treatments. Despite this, they have not historically received much attention in terms of investment and research effort, nor do they now. In very recent years, thanks to the involvement of several nonprofit organizations, the chemotherapeutic options have expanded with the introduction of the first combination therapy. The optimal efficacy and safety of nifurtimox – eflornithine combination against second-stage human African trypanosomiasis is an encouraging first step towards simpler and more affordable therapies. Along the same line, I propose that single chemical entities able to modulate more than one target may prove more efficacious and tolerable than the available arsenal of drugs. Herein, I discuss the pros and cons of this approach, together with examples taken from the recent literature.
Export Options
About this article
Cite this article as:
Laura Bolognesi Maria, Multi-Target-Directed Ligands as Innovative Tools to Combat Trypanosomatid Diseases, Current Topics in Medicinal Chemistry 2011; 11 (22) . https://dx.doi.org/10.2174/156802611798184391
DOI https://dx.doi.org/10.2174/156802611798184391 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In-Vitro and In-Vivo Pharmacological Activities with Phytochemical Evaluation of Methanolic Extract of Microcos paniculata Stem Barks
Current Drug Therapy Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology Long-Term Multimodal Therapy (Verapamil Associated with Propolis, Blueberry, Vitamin E and Local Diclofenac) on Patients with Peyronie's Disease (Chronic Inflammation of the Tunica Albuginea). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Determination of Propranolol and Naproxen in Urine by using Excitation-Emission Matrix Phosphorescence Coupled with Multivariate Calibration Algorithms
Current Pharmaceutical Analysis Insulin Delivery Systems for Controlling Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Exploring the Technology Landscape of 7TMR Drug Signaling Profiling
Current Topics in Medicinal Chemistry Pain in Patients with Parkinson’s Disease; A Pain-related Evoked Potential Study
Neuroscience and Biomedical Engineering (Discontinued) Recent Progress of Imaging Agents for Parkinson’s Disease
Current Neuropharmacology Present Situation of the Development of Cellular-Type Hemoglobin-Based Oxygen Carrier (Hemoglobin-Vesicles)
Current Drug Discovery Technologies Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Current Pharmaceutical Design Current Quest in Natural Bioactive Compounds for Alzheimer’s Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence
Current Drug Targets Diagnosis and Therapeutic Approaches to Transthyretin Amyloidosis
Current Medicinal Chemistry A Dig Deep to Scout the Pharmacological and Clinical Facet of Garlic (<i>Allium sativum</i>)
Current Traditional Medicine Nonviral Gene Therapy
Current Gene Therapy